Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLELE study of tabelecleucel in EBV-associated post-transplant lymphoproliferative disease after rituximab failure
2017-002949-30Phase 3Unknown
- Sponsor
- Atara Biotherapeutics
- Start
- Nov 2019
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of tabelecleucel in Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) (2 cohorts), sponsored by Atara Biotherapeutics. Primary endpoint: Overall response rate. Status: unknown.
02
Drugs
tabelecleucel
03
Conditions
Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD)
Beyond the preview
Go deeper on 2017-002949-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002949-30.